Affiliation:
1. National Medical Research Center for Oncology, Ministry of Health of Russia
2. Rostov State Medical University, Ministry of Health of Russia
Abstract
Introduction. Colorectal cancer is a frequently diagnosed disease being in the third place among oncological diseases both in incidence and mortality. Currently, researchers focus on development of more accessible and reliable biomarkers of colorectal cancer to overcome the problems in diagnosis and progression prognosis of this pathology.Aim. To investigate characteristics of microRNA expression in circulating tumor cells (CTC) of patients with colorectal cancer. Materials and methods. The study included blood samples from 299 patients with colon cancer, stages II (T3–4N0M0), III (T1–4N1–2M0) and IV (T1–4N0–2M1). Circulating tumor cells were identified using EpCAM marker detection system. Relative expression of hsa-let-7i-5p, hsa-miR-126-5p, hsa-miR-143-3p, hsa-miR-21-5p, hsa-miR-25-3p, hsa-miR-26a-5p, hsa-miR-92a-3p micro RNA in CTC was measured using polymerase chain reaction.Results. Positive CTC status was observed in 188 (62.9 %) of 299 patients, negative in 111 (37.1 %). In the patient group with pT1–2 tumors, the majority of patients did not have CTC (53.3 %). In other patients with pT1–2 disease, the number of CTC was 1.2 and 4.4 times lower than in patients with pT3 and pT4 disease, respectively. In pT4, 1–3 CTC were found 2.7 and 1.7 times more frequently, 3 CTC 1.4 times more frequently than in pT1–2 and pT3, respectively (p ≤0.05). Presence of metastatic lesions increases the probability of CTC detection by the factor of 2.1: in metastases, >3 CTC were observed 60.1 times more frequently than in M0 (p ≤0.05). Expression of hsa-miR-143-3p and hsa-miR-26a-5p microRNA in CTC of patients with stage III colorectal cancer was respectively 2.5 and 5 times lower than in patients with stage II disease (p <0.05) and expression of hsa-miR-21-5p and hsa-miR-92a-3p microRNA was respectively 3.2 and 3 times higher (p <0.05). In CTC of patients with stage IV colorectal cancer, the relative level of expression of hsa-miR-143-3p and hsa-miR-26a-5p was respectively 4.6 and 5.3 times lower (p <0.05) compared to the level of expression in stage II disease, and hsa-miR-126-5p, hsa-miR-21-5p, hsa-miR-25-3p and hsa-miR-92a-3p expression levels were respectively 2.6, 4.6, 2.6 and 5.0 times higher (p<0.05) (statistically significant results).Conclusion. The level of microRNA expression in CTC can be used for differential diagnosis of regional and distant metastases.
Publisher
Publishing House ABV Press
Subject
Cancer Research,Biochemistry (medical),Genetics (clinical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
Reference32 articles.
1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 2018;68(6):394–424. DOI: g/10.3322/caac.21492
2. Siegel R.L., Torre L.A., Soerjomataram I. et al. Global patterns and trends in colorectal cancer incidence in young adults. Gut 2019;68(12):2179–85. DOI: 10.1136/gutjnl-2019-319511
3. Lee J.K., Liles E.G., Bent S. et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 2014;160(3):171–81. DOI: 10.7326/M13-1484
4. Bray C., Bell L.N., Liang H. et al. Colorectal cancer screening. WMJ 2017;116(1):27–33. 5. Gerlinger M., Rowan A.J., Horswell S. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883–92. DOI: 10.1056/ NEJMoa1113205
5. Brown S.R., Hicks T.C., Whitlow C.B. Diagnostic and therapeutic colonoscopy. Shackelford’s Surg Alimentary Tract 2019;2:1689–99. DOI: 10.1016/B978-0-323-40232-3.00145-X